Combined blockade of IL-17A and IL-17F may prevent the development of experimental colitis

Immunotherapy

Volumn 5, Issue 9, 2013, Pages 923-925

  McLean, Leon P ^a   Cross, Raymond K ^a   Shea Donohue, Terez ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Crohn's disease; IL 17A; IL 17F; Secukinumab; Th17; Ulcerative colitis

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 17 ANTIBODY; INTERLEUKIN 17F;

CD4+ CD25+ T LYMPHOCYTE; COLITIS; CROHN DISEASE; IMMUNE DEFICIENCY; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; LAMINA PROPRIA; NONHUMAN; NOTE; PRIORITY JOURNAL; STABLE EXPRESSION; TH17 CELL;

ANIMALS; COLITIS; FEMALE; INFLAMMATION; INTERLEUKIN-17; INTESTINES; TH17 CELLS;

EID: 84883591833     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.13.87     Document Type: Note

References (13)

1. Brand S. Crohn's disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn's disease. Gut 58, 1152-1167 (2009).
2. Dubin PJ, Kolls JK. Th17 cytokines and mucosal immunity. Immunol. Rev. 226, 160-171 (2008).
3. Langrish CL, Chen Y, Blumenschein WM et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med. 201, 233-240 (2005).
4. Rovedatti L, Kudo T, Biancheri P et al. Differential regulation of interleukin 17 and interferon gamma production in inflammatory bowel disease. Gut 58, 1629-1636 (2009).
5. Miossec P, Kolls JK. Targeting IL-17 and Th17 cells in chronic inflammation. Nat. Rev. Drug Discov. 11, 763-776 (2012).
6. Hueber W, Sands BE, Lewitzky S et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 61, 1693-1700 (2012).
7. Leppkes M, Becker C, Ivanov II et al. RORg-expressing Th17 cells induce murine chronic intestinal inflammation via redundant effects of IL-17A and IL-17F. Gastroenterology 136, 257-267 (2009).
8. Wu S, Rhee KJ, Albesiano E et al. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat. Med. 15, 1016-1022 (2009).
9. Zhang Z, Zheng M, Bindas J, Schwarzenberger P, Kolls JK. Critical role of IL-17 receptor signaling in acute TNBS-induced colitis. Inflamm. Bowel Dis. 12, 382-388 (2006).
10. O'Connor W Jr, Kamanaka M, Booth CJ et al. A protective function for interleukin 17A in T cell-mediated intestinal inflammation. Nat. Immunol. 10, 603-609 (2009).
11. Yang XO, Chang SH, Park H et al. Regulation of inflammatory responses by IL-17F. J. Exp. Med. 205, 1063-1075 (2008).
12. Wedebye Schmidt EG, Larsen HL, Kristensen N et al. Th17 cell induction and effects of IL-17A and IL-17F blockade in experimental colitis. Inflamm. Bowel Dis. 19(8), 1567-1576 (2013).
13. Sandborn WJ, Gasink C, Gao LL et al. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N. Engl. J. Med. 367, 1519-1528 (2012).